Pills Menu Home Articles hepatitis a Forum Links Podcast Downloads Pictures Polls Help-FAQ Contacts Tag Cloud Search Site Site Map care resources Sign in Register Members
Members: 2116 Newest Member: Ste Members | JOIN Search Pills Downloads Articles Links News Pictures Comments regional Omeprazole decreases antiplatelet effect of clopidogrel + ASA Posted September 5, 2008 by admin. - Cardiovascular - reports to:
The antiplatelet activity of combination therapy aspirin / clopidogrel undergoes a significant decrease when combined with the simultaneous intake of omeprazole. An observational study showed that the antiplatelet activity of clopidogrel, a drug widely used for its effectiveness in atherothrombotic diseases, was decreased hepatitis a in patients taking proton pump inhibitors. This double-blind hepatitis a trial has recruited all patients undergoing stent implantation taking hepatitis a aspirin (75 mg / day) and clopidogrel (usual hepatitis a loading dose followed by 75 mg / day) were randomized to receive omeprazole (20 mg / day) or placebo for a period of 7 days. The antiplatelet activity of clopidogrel was tested in the first and seventh hepatitis a day in both groups by measuring the VASP (vasodilator-stimulated phosphoprotein) hepatitis a expressed as PRI (Platelet Reactivity Index). The data analysis of 124 patients enrolled showed that on the first day of the PRI average was 83.2% (standard deviation [SD] 5.6) and 83.9% (SD 4.6) in the placebo and omeprazole, respectively, and on the seventh day 39.8% ( DS 15.4) and 51.4% (SD 16.4), (p <0.0001). Source: Gilard M. et al. Influence of Omeprazole on the Antiplatelet Action of Clopidogrel Associated With Aspirin. The Randomized, Double-Blind OCLA (Omeprazole Clopidogrel Aspirin) Study. J Am Coll Cardiol, 2008; 51: 256-260 Comment by Marco Grassi The results of this study demonstrate that the activity of antiplatelet therapy combined aspirin hepatitis a / clopidogrel (usually used in patients undergoing coronary stent implantation) undergoes hepatitis a a significant decrease when combined with the simultaneous intake of a PPI (proton pump inhibitor), omeprazole, in this case. PPIs are elective indication as gastroprotective hepatitis a in patients at high risk of gastrointestinal bleeding who take NSAIDs or aspirin but are also increasingly used in patients with low or very low risk or even as "gastric coverage" in patients on polytherapy. These preliminary results, which our impact clinical remains to be determined with any ad hoc studies, should prompt us to reflect on the habit increasingly widespread systematically to associate an IPP to antiplatelet therapies. Particular caution dovrebbere be placed in patients taking clopidogrel after stenting, especially those who are medicated at greater risk of occlusion. Read: 3114 | Back | | | | | ARCHIVE | SEARCH PILLS | LAST MONTH | THE MOST LETTE Add - Comments Comments flash before you must log in. For comments articulated use the Forum
19:58 hours | 15,161,122 accesses | Users Online: 357
No comments:
Post a Comment